Update
$BriaCell Therapeutics (BCTX.US)$ BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
5 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)
Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician's choice
Interim data analysis planned at 144 events (deaths) could provide full approval and marketing authorization
Pivotal Phase 3 study patient enrollment completion is expected in mid-2025
No serious adverse events related to Bria-IMT™ have been reported to date
5 MINUTES AGO, 7:50 AM EDT
VIA GLOBENEWSWIRE
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)
Primary endpoint is overall survival (OS) with Bria-IMT™ regimen plus Check Point Inhibitor (CPI) vs treatment of physician's choice
Interim data analysis planned at 144 events (deaths) could provide full approval and marketing authorization
Pivotal Phase 3 study patient enrollment completion is expected in mid-2025
No serious adverse events related to Bria-IMT™ have been reported to date
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
HannChau : @Pearls Dad are you still in this stock?